Organisation paid for research Program year 2022 Source: CMS Open Payments

Avail Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$467,349

99 payments

Through program year 2022, Avail Clinical Research is reported as receiving $467,349 in research payments, across 99 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2022	Research	$8,413	2
2020	Research	$151,698	31
2019	Research	$307,238	66

Breakdown

Who paid Research payments · program years 2019–2022

Pfizer Inc. $458,936 97 payments
Amgen Inc. $8,413 2 payments

Studies the money was for Research payments · program years 2019–2022

A Phase 3 Randomized Observerblinded Study to Evaluate the Immunogenicity Safety and Tolerability of 2 Doses Compared to 3 Doses of Clostridium Difficile Vaccine in Adults 50 Years of Age and Older $267,308 37 payments
Phase III Lot Consistency Trial $90,794 17 payments
A Phase 2 Randomized Openlabel Trial to Evaluate the Safety and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine Given With Or Separately From 13Valent Pneumococcal Conjugate Vaccine in Healthy Infants $34,891 18 payments
A Phase 1 Openlabel Randomized 2Treatment 2Period Singledose Crossover Study 2Part Design to Evaluate the Bioequivalence and Tolerability of Testosterone Cypionate Following Intramuscular Im Injection in Healthy Hypogonadal Male Subjects $34,041 5 payments
A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccinenaive Adults 18 Through 49 Years of Age $20,358 5 payments
A Phase 2 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age $10,270 2 payments
Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa $8,413 2 payments
Phase 2AB Safety and Efficacy Study of Pf06700841 in Patients With Moderate Psoriasis $899 7 payments
Phase 2AB Safety and Efficacy Study of Pf06700841 in Atopic Dermatitis Patients $375 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.